Khanna A, Gish R, Winter S C, Nyhan W L, Barshop B A
Department of Surgery and Center for Gut Rehabilitation and Transplantation, Transplant Center, Cleveland Clinic, Cleveland, OH, 44195, USA.
Department of Gastroenterology, Stanford University, Palo Alto, CA, 94305, USA.
JIMD Rep. 2016;25:87-94. doi: 10.1007/8904_2015_480. Epub 2015 Jul 29.
Liver transplantation has been reported in patients with methylmalonic acidemia (MMA), but long-term outcome is controversial. Many patients with other approved indications for liver transplantation die before donor grafts are available. A 28-year-old man with MMA underwent cadaveric liver transplantation. His liver was used as a domino graft for a 61-year-old man with primary sclerosing cholangitis, who had low priority on the transplant waiting list. Surgical outcome was successful, and after transplantation both patients have excellent graft function. The patient with MMA showed substantial decrease in methylmalonate in urine (from 5,277 ± 1,968 preoperatively to 1,068 ± 384 mmol/mol creatinine) and plasma (from 445.9 ± 257.0 to 333.3 ± 117.7 μmol/l) over >1-year follow-up, while dietary protein intake increased from 0.6 to 1.36 ± 0.33 g/kg/day. The domino recipient maintained near-normal levels of plasma amino acids but did develop elevated methylmalonate in blood and urine while receiving an unrestricted diet (peak plasma methylmalonate 119 μmol/l and urine methylmalonate 84-209 mmol/mol creatinine, with 1.0-1.9 g/kg/day protein). Neither patient demonstrated any apparent symptoms of MMA or metabolic decompensation during the postoperative period or following discharge.
Liver transplantation substantially corrects methylmalonate metabolism in MMA and greatly attenuates the disease. In this single patient experience, a liver from a patient with MMA functioned well as domino graft although it did result in subclinical methylmalonic acidemia and aciduria in the recipient. Patients with MMA can be considered as domino liver donors for patients who might otherwise spend long times waiting for liver transplantation.
已有甲基丙二酸血症(MMA)患者接受肝移植的报道,但长期预后存在争议。许多有其他肝移植适应证的患者在获得供体移植物之前就死亡了。一名28岁的MMA男性患者接受了尸体肝移植。他的肝脏作为多米诺移植物用于一名61岁的原发性硬化性胆管炎男性患者,该患者在移植等待名单上优先级较低。手术结果成功,移植后两名患者的移植物功能均良好。在超过1年的随访中,MMA患者尿液中的甲基丙二酸显著减少(从术前的5277±1968降至1068±384 mmol/mol肌酐),血浆中的甲基丙二酸也显著减少(从445.9±257.0降至333.3±117.7 μmol/l),而饮食蛋白质摄入量从0.6增加到1.36±0.33 g/kg/天。多米诺受体的血浆氨基酸水平维持在接近正常水平,但在接受无限制饮食时,血液和尿液中的甲基丙二酸确实升高(血浆甲基丙二酸峰值为119 μmol/l,尿液甲基丙二酸为84 - 209 mmol/mol肌酐,蛋白质摄入量为1.0 - 1.9 g/kg/天)。两名患者在术后期间或出院后均未表现出任何明显的MMA症状或代谢失代偿。
肝移植可显著纠正MMA中的甲基丙二酸代谢并大大减轻该疾病。在这例单患者经验中,MMA患者的肝脏作为多米诺移植物功能良好,尽管这确实导致受体出现亚临床甲基丙二酸血症和酸尿症。MMA患者可被视为多米诺肝供体,用于那些否则可能要长时间等待肝移植的患者。